||Clofibric acid is an antilipemic agent that is the biologically active metabolite of CLOFIBRATE.
||Seratrodast (INN), a thromboxane A2 (TXA2) receptor (TP receptor) antagonist, is mainly used in the therapy of asthma. It was the first TP receptor antagonist developed as an anti-
||Pioglitazone is an insulin sensitizing agent and thiazolidinedione that is indicated for the treatment of type 2 diabetes. Pioglitazone has been linked to rare instances of acute l
||Pioglitazone Hydrochloride is the hydrochloride salt of an orally-active thiazolidinedione with antidiabetic properties and potential antineoplastic activity.
||Rosiglitazone is an insulin sensitizing agent and thiazolidinedione that is indicated for the treatment of type 2 diabetes. Rosiglitazone has been linked to rare instances of acute
||Dexibuprofen, S(+)-ibuprofen, is a non-steroidal anti-inflammatory drug (NSAID), inhibiting cyclooxygenase (COX).
||Mesalamine is an anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHA
||Triflusal is a 2-acetoxy-4-trifluoromethylbenzoic acid and it is an aspirin chemically-related molecule but not a derivative.
||Bezafibrate is an antilipemic agent that lowers CHOLESTEROL and TRIGLYCERIDES. It decreases LOW-DENSITY LIPOPROTEINS and increases HIGH-DENSITY LIPOPROTEINS.
||Repaglinide is a benzoic acid derivative that stimulates insulin secretion from the pancreas and is used in the therapy of type 2 diabetes. Repaglinide has been linked to rare inst
||Fenofibrate is a peroxisome proliferator receptor alpha agonist. Fenofibrate is a synthetic phenoxy-isobutyric acid derivate and prodrug with antihyperlipidemic activity.
||Daidzein is an isoflavone extract from soy, which is an inactive analog of the tyrosine kinase inhibitor genistein. It has antioxidant and phytoestrogenic properties.
||Ciprofibrate is a fibrate derivative with antilipidemic activity.
||Clofibrate is an aryloxyisobutyric acid derivate with antihyperlipidemic activity.
||Fenofibric Acid is the active form of fenofibrate, a synthetic phenoxy-isobutyric acid derivate with antihyperlipidemic activity.
||Gemfibrozil interacts with peroxisome proliferator-activated receptors (PPARalpha) resulting in PPARalpha-mediated stimulation of fatty acid oxidation and an increase in lipoprotei
||Glipizide is a short-acting, second-generation sulfonylurea with hypoglycemic activity.
||Rosiglitazone Maleate is the maleate salt of rosiglitazone, an orally-active thiazolidinedione with antidiabetic properties and potential antineoplastic activity.
||Nateglinide is an oral hypoglycemic agent and amino acid derivative that stimulates insulin secretion from the pancreas and is used in the therapy of type 2 diabetes. Nateglinide h
||JW 55 is an effective and selective β-catenin signaling pathway inhibitor, works by inhibition of the PARP domain of tankyrase 1 and tankyrase 2 (TNKS1/2).
||GSK3787 is a specific and irreversible PPARδ inhibitor（pIC50= 6.6）.
||GW9662 is a specific PPARγ antagonist (IC50: 3.3 nM, in a cell-free assay), with 100 to 1000-fold functional selectivity for PPARγ than PPARα/δ in cells.
||Pirinixic Acid is a synthetic thiacetic acid derivative used in biomedical research, carcinogenic Pirinixic acid is a peroxisome proliferator that activates specific peroxisome pro
||Ramatroban (BAY u3405) is a thromboxane A(2) (TxA(2)) antagonist marketed for allergic rhinitis. It has been used in trials studying the treatment of Asthma.
||FH535, a Wnt/β-catenin signaling and PPAR inhibitor, exhibits anti-tumor activities.
||GSK0660 is an antagonist and inverse agonist of PPARβ/δ.
||Extracted from whole herb of Gynostemsma pentaphyllum(Thunb.)Mak.;Store the product in sealed, cool and dry condition
||Magnolol is a dual agonist of RXRα( EC50=10.4 μM) and PPARγ(EC50=17.7 μM). It blocks TNF-α-induced NF-KB activation.
||WIKI4 is a potent inhibitor of Wnt/β-catenin signaling and tankyrase 2 (TNKS2).
||Abietic Acid is the primary component of resin acid isolated from rosin.
||Troglitazone is a PPARγ agonist with anti-inflammatory and anti-tumor activity.
||NVP-TNKS656 is a highly potent, selective, and orally active TNKS2 inhibitor.
||XMD8-87 is a TNK2 inhibitor with activity in the inhibition of TNK2 phosphorylation. XMD8-87 and XMD16-5 potently inhibit phosphorylation of TNK2 truncation mutations found in soli
||XMD16-5 is a TNK2 inhibitor. TNK2 genomic amplification has been associated with late-stage or metastatic lung and prostate Ys. Overexpression of TNK2 promoted metastasis in a mous
||Protopanaxatriol, a major ginseng constituent, is a novel PPARγ antagonist.
||GW501516 is a effective and highly specifc PPARβ/δ agonist (EC50: 1 nM), with 1000-fold selectivity over hPPARα/γ.
||GW0742 (GW610742) is an effective and specific PPARδ agonist (EC50: 1 nM/1.1 μM/2 μM, for human PPARδ/α/γ).
||Rosiglitazone HCl is a blood glucose-lowering drugs, stimulating insulin secretion by binding to the PPAR receptors in fat cells.
||T0070907(IC50=1 nM) , an effective and specific PPARγ inhibitor, with the >800-fold selectivity over PPARα and PPARδ.
||AZ6102 is a potent TNKS1/2 inhibitor that has 100-fold selectivity against other PARP family enzymes and shows IC50 of 5 nM for Wnt pathway inhibition in DLD-1 cells.
||Palmitoylethanolamide(PEA) , an endogenous fatty acid amide, activates PPAR-α selectively in vitro (EC50=3.1±0.4 μM）.
||SR-18292 is a PPAR gamma coactivator-1α (PGC-1α) inhibitor, which increases PGC-1α acetylation, suppresses gluconeogenic gene expression and reduces glucose production in hepato
||Elafibranor is an agonist of the peroxisome proliferator-activated receptor-α (PPAR-α) and peroxisome proliferator-activated receptor-δ (PPAR-δ) with EC50 values of 45 and 175
||LB-100 is a water soluble protein phosphatase 2A (PP2A) inhibitor. Phase 1.
||MBX-8025 has been used in trials studying the treatment of Hyperlipidemia.
||Bilobetin ameliorates insulin resistance by PKA-mediated phosphorylation of PPARα in rats fed a high-fat diet.
||BMS-687453 is a potent and selective PPAR alpha agonist, with an EC(50) of 10 nM for human PPARalpha and approximately 410-fold selectivity vs human PPARgamma in PPAR-GAL4 transact
||Oroxin A is a partial PPARγ agonist that can activate PPARγ transcriptional activation in vitro and in vivo. Oroxin A also exhibited inhibitory activity against α-glucosidase an
||Alliin is a garlic organosulfur compound that possesses various pharmacological properties.alliin protected against LPS-induced ALI by activating PPARγ, which subsequently inhibit
||Growth hormone releasing peptide
||Growth hormone releasing peptide ia a natual product ,and has anti-inflammatory effects, due to its inhibitory effect on PKC-induced activation of p38, JNK and NF-κB, possibly by
||D-erythro-Sphingosine is a protein kinase C (PKC) inhibitor. D-erythro-Sphingosine (Erythrosphingosine) is also a PP2A activator
||L-165041 is a potent and selective agonist of the nuclear receptor PPARβ and PPARδ(Ki = 9 nM, EC50 = ~500 nM ,respectively)
||Lanifibranor is an agonist of peroxisome proliferator-activated receptors (PPARs) with EC50 values of 1,537, 866, and 206 nM for human recombinant PPARα, PPARβ, and PPARγ, respe
||4'-Methoxychalcone with a variety of pharmacological activities, such as anti-tumor and anti-inflammatory activities.
||Pemafibrate is a highly specific PPARα agonist (EC50: 1 nM).
||GW1929 is a potent PPAR-γ agonist (pKi: 8.84 for human PPAR-γ; pEC50s of 8.56 and 8.27 for human and murine PPAR-γ).
||Balaglitazone is a selective partial agonist for PPARγ (EC50: 1.351 μM for human PPARγ).
||CDDO-Im is an activator of Nrf2 and PPAR (Kis: 232/344 nM for PPARα/PPARγ).
||Fucosterol is isolated from E. stolonifera with anti-diabetic, anti-adipogenic and anti-cancer activities. It regulates adipogenesis via modulation of PPARα and C/EBPα expression
||DG172 (dihydrochloride) is an antagonist of PPARβ/δ(IC50 : 27 nM).
||LJ570 is the first PPARα/γ dual agonist (PPARα,PPARγ with EC50s of 1.05 and 0.12 μM, respectively[)
||Sakuranetin, a flavanone phytoalexin from ultraviolet-irradiated rice leaves, it has antifungal, antimutagenic, anti-inflammatory and antioxidant effects
||13-Methylberberine shows anti-adipogenic effect on 3T3-L1 adipocytes, it has potential as an anti-obesity drug
||Gentianine has anti-diabetic, antipsychotic, anti-inflammatory, hypotensive, and diuretic actions, it could be developed as a safe antihypertensive drug.
||Isosilybin A is a partial PPARγ agonist, it significantly induced ABCA1 protein expression, it inhibited both monophenolase (IC50=1.7-7.6μM) and diphenolase (IC50=12.1-44.9μM) o
||Soyasaponin Aa and soyasaponin Ab dose-dependently markedly inhibit adipocyte differentiation and expression of various adipogenic marker genes, through the downregulation of the a
||Uvaol has anti-inflammatory, anti-proliferative, and vasorelaxing activities.
||Licochalcone E is a potential LXRβ agonist.
||Glabrone shows antiviral activity against influenza virus.
||Glycyrin, one of the main PPAR-gamma ligands of licorice, can significantly decrease the blood glucose levels of genetically diabetic KK-A(y) mice.
||Kudinoside D exerts anti-adipogenic effects through modulation of adipogenic transcription factors via AMPK signaling pathway.
||PPARδ agonist is an agonist of PPARδ.
||Pparδ agonist 2
||Pparδ agonist 2 is an agonist of PPARδ.
||13-Oxo-9E,11E-octadecadienoic acid, an isomer of 9-oxo-ODA, is a potent PPARα activator derived from tomato juice. 13-Oxo-9E,11E-octadecadienoic acid decreases plasma and hepatic
||Aleglitazar is being developed for the treatment of type II diabetes; It is currently in phase III clinical trials. In preliminary clinical studies, Aleglitazar has been demonstrat
||AVE-8134 is an agonist of PPARα. For human and rodent PPARα receptor, the EC50 values are 100 and 3000 nM, respectively.
||Ankaflavin is isolated from Monascus-Fermented red rice and is a PPARγ agonist with anti-inflammatory activity. It shows the selective cytotoxic effect and induces cell death on c
||Mifobate is a potent and specific antagonist of PPARγ. Mifobate shows antiobesity, antidiabetic and antiatherosclerotic effects.
||Chiglitazar is a dual agonist of PPARα/γ (EC50s: 1.2, 0.08, and 1.7 μM for PPARα, PPARγ, and PPARδ).
||Ertiprotafib is a PTP1B, IkB kinase β (IKK-β), and a dual PPARα and PPARβ agonist inhibitor ( IC50s: 1.6 μM for PTP1B, 400 nM for IKK-β, an EC50 of ~1 μM for PPARα/PPARβ).
||Fonadelpar is an agonist of PPARδ. It also is used in the research of neuroparalytic keratopathy.
||VCE-004.8 is a specific dual agonist of PPARγ and CB2 receptor with potent anti-inflammatory activity. VCE-004.8 attenuates adipogenesis and prevents diet-induced obesity.
||GSK376501A is a selective modulator of peroxisome proliferator-activated receptor gamma (PPARγ). It is used for the treatment of type 2 diabetes mellitus.
||GW7647 is a potent agonist of PPARα (EC50s: 6 nM, 1.1 μM, and 6.2 μM for human PPARα, PPARγ, and PPARδ, respectively).
||Imiglitazar is a potent and dual human PPARα and PPARγ1 agonist (EC50: 67 and 31 nM).
||Indeglitazar is orally available pan-agonist of PPAR (PPAR subtypes alpha (α), delta (δ), and gamma (γ)).
||Inolitazone dihydrochloride is a novel high-affinity agonist of PPARγ. It is dependent upon PPARγ for its biological activity (IC50: 0.8 nM for growth inhibition).
||Inolitazone a novel high-affinity agonist of PPARγ. It is dependent upon PPARγ for its biological activity (IC50: 0.8 nM for growth inhibition).
||LG100754 is an insulin sensitizer that functions through RXR. LG100754 is an RXR dimer modulator. LG100754 acts as an RXR: RXR homodimer antagonist, but functions as an agonist tow
||Ketorolac D5 is a deuterium labeled Ketorolac. Ketorolac is a non-steroidal anti-inflammatory agent, acting as a nonselective COX inhibitor, with IC50s of 20 nM for COX-1 and 120 n
||MA-0204 is a highly selective and orally available peroxisome proliferator-activated receptor δ (PPARδ) modulator (EC50s: 0.4 nM, 7.9 nM and 10 nM for human, mouse and rat PPARδ
||Maytansinol inhibits microtubule assembly and causes microtubule disassembly in vitro.
||PPAR agonist 1
||PPAR agonist 1 is an agonist of PPAR α/γ, used for reducing blood glucose, lipid levels, reducing body weight, and lowering cholesterol.
||PPARα-MO-1 is a potent modulator of PPARα extracted from patent WO/2004/110982A1 (formula I).
||RG-12525 is a PPAR-gamma agonist (IC50: appr 60 nM) and a potent inhibitor of CYP3A4 (Ki: 0.5 µM). RG-12525 is a specific and competitive antagonist of the peptidoleukotrienes, LT
||Tesaglitazar causes interstitial mesenchymal cell DNA synthesis and fibrosarcomas in subcutaneous tissues in rats. Tesaglitazar is a dual peroxisome proliferator-activated receptor
||GW6471 is an antagonist of PPARα with IC50 of 0.24 μ M. GW6471 enhances the binding affinity of the PPAR α ligand-binding domain to the co-repressor proteins SMRT and NCoR.
||1β-Hydroxy-2-oxopomolic acid inhibits adipocyte differentiation through downregulation of various adipocytokines by blocking PPARγ and C/EBPα expression.
||12-O-Methylcarnosic acid is a diterpene carnosic acid isolated from the acetone extract of Salvia microphylla, is an active constituent of 5α-reductase inhibition with an IC50 val
||15-Methoxypinusolidic acid has anti-inflammatory effects, it inhibits LPS-induced iNOS expression and NO production, independent on MAPK and NF-kappaB. 15-Methoxypinusolidic acid s
||6-Acetonyldihydrochelerythrine exhibits significant antioxidant activities, it exhibits significant anti-HIV activity in H9 lymphocytes with EC50 and TI (Therapeutic Index) values
||7,8-Didehydrocimigenol can be used for the treatment of cardiovascular disorders such as atherosclerosis. It upregulates PPAR-γ in EC inhibits NF-kB activity of TNF-α-activated E
||Ailanthoidol has anti-inflammatory activity, it inhibits inflammatory reactions by macrophages and protects mice from endotoxin shock. It also possesses potential as a chemoprevent
||Catalposide possesses antioxidant, anti-apoptotic, anti-microbial, anti-tumoral, and anti-inflammatory properties. Catalposide is a potent inducer of HO-1 and HO-1 induction is res
||Cimiside E has anti-inflammatory activity, it selectively inhibits TNF-α-induced expression of VCAM-1 at least by upregulation of PPAR-γ, and signals for ERK1/2, PI3K, and PKC ar
||Erycibelline has antiobesity activity, it may be a useful therapeutic agent for body weight control by downregulating adipogenesis and lipogenesis.
||Ficusin has antioxidant, antilipidemic and antidiabetic effects, it can lower the levels of fasting blood glucose, plasma insulin, body weight gain in HFD-STZ induced diabetic rats
||Gallocatechin gallate has strong antioxidative, and anti-obesity activities, it inhibits 3T3-L1 differentiation and lipopolysaccharide induced inflammation through MAPK and NF-Îº
||Kaerophyllin has anti-fibrotic effects, it can protect the rat liver from TAA-caused injury and fibrogenesis by suppressing hepatic inflammation and inhibiting HSC activation, poss
||Kihadanin B can repress the adipogenesis by decreasing lipid accumulation through the suppression of the Akt-FOXO1-PPARγ axis in 3T3-L1 adipocytes.
||Moringin is a modulator of neuroinflammation via the β-catenin-PPARγ axis, it can activate Wnt canonical pathway by inhibiting GSK3β in a mouse model of experimental autoimmune
||Norlichexanthone has the potential to treat and/or prevent lifestyle-related diseases, including metabolic syndrome, type 2 diabetes, atherosclerosis and cardiovascular diseases.No
||Pueroside B may can treat coronary heart disease, it can interact with two or more targets[peroxisome proliferator activated receptor γ (PPAR-γ), angiotensin-converting enzyme (A
||Tagitinin A is a plant insecticidal compound, it has phytotoxic activity, it shows significant inhibition of wheat coleoptile growth, seed germination, and the growth of STS and we
||Tetramethylkaempferol is a PPARγ agonist, it can improve insulin sensitivity by increasing the levels of adiponectin, an important adipocytokine associated with insulin sensitivit
||Tirotundin is a PPARα/γ dual agonist, it exerts anti-diabetic effect through PPARγ pathway. It shows anti-inflammatory activity, it inhibits inhibit the activation of NF-kappa B
||Oleoylethanolamide is a high affinity endogenous agonist of PPAR-α.
||Adelmidrol is an anti-inflammatory ethanolamide derivative of azelaic acid.
||Choline Fenofibrate is a choline formulation of fenofibrate, a synthetic phenoxy-isobutyric acid derivate and prodrug with antihyperlipidemic activity.
||Astaxanthin is a keto-carotenoid in the terpenes class of chemical compounds. It is classified as a xanthophyll but it is a carotenoid with no vitamin A activity. It is present in
||Bavachinin(7-O-Methylbavachin) is a natural compound isolated from the Chinese herb Fructus Psoraleae with potent anti-angiogenic activity.
||Ginsenoside Rg1, one of the main constituents of Panax ginseng, exhibits anti-inflammatory effect.
||INT-131, is a novel, non-thiazolidinedione (TZD), selective peroxisome proliferator-activated receptor (PPAR)gamma modulator, which can be used for the treatment of type 2 diabetes
||G007-LK is a selective inhibitor of TNKS1 and TNKS2, with IC50s of 46 nM and 25 nM, respectively.
||Eupatilin, a flavone derived from Artemisia princepsPampanini, is a PPARα agonist, with pharmacological activity.
||Phytol, a diterpene alcohol from chlorophyll widely used as a food additive and in medicinal fields, shows antinociceptive and antioxidant activities as well as anti-inflammatory a
||Arhalofenate is a selective partial agonist of peroxisome proliferator-activated receptor PPARγ. It is used for the treatment of type 2 diabetes.